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Abstract
Background Obesity is characterized by chronic mild
inflammation and may influence the risk and progression
of cancer.
Purpose The current study is an exploratory analysis of the
effect of a weight loss intervention that emphasized
increased physical activity on inflammatory cytokines
(tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6],
interleukin-8 [IL-8], and vascular endothelial growth factor
[VEGF]) at the end of the 16-week intervention period in
overweight breast cancer survivors.
Methods Study participants averaged 56 years of age (N=
68). Intervention participants (n=44 vs. 24 controls)
participated in a cognitive behavioral therapy-based weight
management program as part of an exploratory randomized
trial. The intervention incorporated strategies to promote
increased physical activity and diet modification. Baseline
and 16-week data included height, weight, body composi-
tion, physical activity level, and biomarkers IL-6, IL-8,
TNF-α, and VEGF.
Results Weight loss was significantly greater in the inter-
vention group than controls (−5.7 [3.5] vs. 0.2 [4.1] kg, P<
0.001). Paired t tests noted favorable changes in physical
activity level (P<0.001 intervention, P=0.70 control),
marginally lower IL-6 levels (P=0.06 intervention, P=
0.25 control) at 16 weeks for participants in the intervention
group, and lower TNF-α levels for participants in the
intervention (P<0.05) and control groups (P<0.001).
Increased physical activity was associated with favorable
changes in IL-6 for participants in the intervention group
(R
2=0.18; P<0.03).
Conclusion Favorable changes in cytokine levels were
observed in association with weight loss in this exploratory
study with overweight breast cancer survivors.
Keywords Weightloss.Physicalactivity.Exercise.
Inflammatoryfactors.Obesity.Breastcancersurvivors
Introduction
Breast cancer is the most common invasive cancer among
women in developed countries. It accounts for 26% of
incident cancers and 15% of cancer deaths among women
in the US, with an estimated 180,000 women diagnosed
with breast cancer in 2008 [1]. Most breast cancers are now
diagnosed at a localized stage, which is associated with a 5-
year survival rate of 96% [1]. In addition, improvements in
initial treatments have resulted in an ever-increasing
number of breast cancer survivors [1, 2]. Recurrence, risks
for second primary cancers, and comorbidities, such as
diabetes, cardiovascular disease, and osteoporosis, are
issues that need to be considered in long-term management
of these women [3, 4].
Overweight or obesity is a negative prognostic factor in
both pre- and postmenopausal breast cancer [5, 6], and it is
increasingly being recognized as a medical condition that is
characterized by chronic mild inflammation [7]. Several
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Published online: 19 February 2011mechanisms have been proposed to explain the adverse
effect of overweight on prognosis after the diagnosis of
breast cancer, including the unfavorable effects of obesity
on circulating levels of inflammatory cytokines [8].
Inflammatory cytokines, such as interleukin-6 (IL-6),
interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and
vascular endothelial growth factor (VEGF), have been
consistently associated with breast pathology, and specifi-
cally, the development of breast cancer [9]. This is possibly
a result of their regulatory impact on proliferation of breast
cancer cells through estrogen production [10]. Even though
the exact processes with which these cytokines may
influence breast carcinoma is still under debate [11], higher
levels of IL-6 and IL-8 are both associated with advanced
disease and/or metastases in breast cancer patients [12]. In
addition to influencing the risk and progression of cancer
[13, 14], research efforts have identified chronic mild
inflammation as an independent predictor of several other
chronic diseases and mortality [15].
One probable explanation for the relationship between
obesity and inflammation is the finding that adipose tissue
functions as a major secretory organ for inflammatory
markers, including TNF-α, IL-6, IL-8, and VEGF [14, 16,
17]. Furthermore, increased production and release of TNF-
α, IL-6, and IL-8 by adipose tissue are associated with
degree of obesity [8, 16]. Conversely, weight loss has been
associated with a reduction in these inflammatory factors
[18]. Most studies evaluating the influence of weight loss
on cytokine levels relied primarily on reduced energy
intake as a behavioral strategy [8, 19]. In a randomized
clinical trial of weight loss and chronic inflammation in
obese adults, Nicklas et al. [15] found that diet-induced
weight loss of 5.7% on average resulted in significant
reductions in concentrations of IL-6 and TNF-α. In a study
with 120 premenopausal obese women (body mass index;
BMI≥30 kg/m
2), a reduction in BMI in the intervention
group was associated with lower serum levels of IL-6 and
C-reactive protein (CRP) [20]. In a recent review, changes
in cytokine levels were noted in all 19 studies designed to
evaluate the effects of weight loss and exercise on markers
of inflammation [19]. The duration of the interventions
ranged from 4-6 weeks to 2 years, with reported weight loss
ranging from 3.2% to 30% of body weight.
Physical activity has also been shown to affect local and
systemic cytokine production. In several studies, exercise
interventions of moderate intensity led to significant
reductions in circulating levels of IL-6, TNF-α, and IL-
8 in healthy individuals and in patients with cardiovascular
disease [21–24]. In other studies, the biological response to
exercise was found to be dependent on the intensity and
duration of the activity [25].
Although several studies have evaluated the relationship
between weight loss, exercise, and circulating cytokine
levels in healthy obese individuals [15, 26] or in individuals
with various health conditions, these relationships have not
been previously examined in overweight breast cancer
survivors. The purpose of this study was to specifically
examine the relationships between weight loss and physical
activity and selected inflammatory markers in breast cancer
survivors. Samples were obtained from women who
participated in a small randomized trial, the Healthy Weight
Management (HWM) Study for Breast Cancer Survivors
(2002-2004), which successfully promoted weight loss in
overweight or obese subjects assigned to the intervention
arm. The current study is an exploratory analysis of the
effect of weight loss and increased physical activity on
inflammatory cytokines TNF-α, IL-6, IL-8 and VEGF at
the end of the 16-week intensive intervention period.
Methods
As a feasibility study, the HWM Study was designed as a
randomized clinical trial to develop and test a multifaceted
approach to promoting healthy weight management in the
target population of overweight or obese breast cancer
survivors. The intervention incorporated new elements of
cognitive behavioral therapy for obesity, such as stronger
emphasis on weight maintenance skills. Increased physical
activity to promote maintenance of (or increase in) lean
body mass, diet modification to facilitate an energy
imbalance, and strategies to improve body image and self-
acceptance were also emphasized as part of the program.
Participants
The participants in the HWM Study were 85 breast cancer
survivors living in San Diego, CA, USA. Primary recruit-
ment procedures included community outreach and net-
working with clinical contacts to receive referrals. Other
strategies included advertising in a major local newspaper
and setting up booths at community events. Finally, a list of
potentially eligible participants from the University of
California, San Diego Cancer Registry was requested. A
letter was sent to those on the list inviting them to contact
the study coordinator if they were interested in participating
in the study.
The inclusion criteria for the study were: 18 years and
older; diagnosed with stage I-IIIA breast cancer within the
previous 14 years; completed initial treatments (i.e.,
surgery, adjuvant chemotherapy, radiation therapy); initial
BMI≥25.0 kg/m
2 (overweight or obese) and a minimum of
15 kg over ideal weight as defined by the Metropolitan Life
Insurance Company tables [27]; willingness and ability to
attend group meetings for 16 weeks and to maintain contact
334 Int.J. Behav. Med. (2011) 18:333–341with the investigators for 1 year; and ability to provide
dietary and exercise data by telephone at prescribed
intervals. An exclusion criterion was the inability to
participate in physical activity because of severe disability
(e.g., severe arthritic conditions).
At screening and recruitment, the ability to participate in
mild and moderate physical activity was assessed with the
Physical Activity Readiness Questionnaire and Health
History Questionnaire, a standard procedure for screening
participants for community-based physical activity pro-
grams of this nature [28]. Following recruitment and written
consent, participants were stratified by BMI [(25.0-29.9 (n=
38) versus >30.0 (n=47)kg/m
2)] and age [<=50 (n=26),
51-65 (n=47), >65 (n =12)], and randomly assigned to
either the group-based intervention program (n=56) or a
control group (n=29), with a 2:1 intervention-to-control
ratio to provide sufficient statistical power for the main
study hypothesis (differential weight loss between groups),
while minimizing subject numbers in this feasibility study.
A test of two-sample comparison of the 16-week weight
change scores was selected with the alpha (type one error)
level set at 0.025 assuming a Bonferroni correction for
multiple hypothesis tests. The power (or one minus the type
two error) was 80%. The standard deviation for weight
change, assumed equal in both groups at 16 weeks, was set
at 5.2 kg based on data from Andersen et al. [29]. This
sample size analysis indicated that a final number of 63
participants (42 intervention and 21 control), after account-
ing for dropouts, would provide an adequately powered
comparison to detect a clinically significant effect size.
Figure 1 includes the CONSORT flow chart for the HWM
study.
Weight Loss Intervention
The intervention sessions were led by trained investigators
and research staff. The program curriculum consisted of
group sessions provided according to the following sched-
ule: weekly for 4 months, and follow-up monthly sessions
through 12 months. The primary goal of the intervention
was to promote regular physical activity and reduced
energy intake in order to facilitate weight loss (Fig. 2).
The group meetings consisted of discussion and education-
al/didactic sessions that covered the content areas, with the
major proportion of time devoted to increasing physical
activity. All intervention subjects also received intensive
individualized telephone-based counseling from the study
coordinator, starting with weekly calls and decreasing in
frequency after the first month (every other week for the
next 2 months, and once a month thereafter). The time
points for data collection from all subjects were baseline,
16 weeks, and 12 months. The group sessions offered to the
treatment study arm was closed-group contingents (with an
average of 12-15 women). To equalize possible seasonal
effects on targeted behaviors and weight change in the two
study arms, wait list subjects were followed concurrent with
intervention group subjects and received general contact
such as mailed communications during the study period. At
study end, they were provided all written intervention
materials and a concise version of the didactic material
along with facilitated discussion in the format of a 2-day
seminar.
Measures
Anthropometric measurements (height, weight, and waist
and hip circumferences) were collected at baseline and
16 weeks using standard procedures, and body composition
was measured with dual energy X-ray absorptiometry
(DXA) using a Lunar DPX-NT densitometer (Lunar/GE
Corp). Whole body, regional body fat, and percent fat were
obtained from total body DXA scans. All scans were
conducted by the same certified technician who was blinded
on the assignment of the intervention for each participant.
Physical activity data were collected at baseline and
16 weeks using the 7-day physical activity recall instrument
developed by Blair et al. [30]. This approach has been shown
to be highly reliable (test-retest reliability=0.99) [31], valid,
and sensitive to the effects of physical activity promotion
programs [30]. This instrument focuses on the participant’s
daily activities over a 7-day period. A telephone interview is
scheduled and the interviewer asks the participant to recall
when and what kind of physical activity they had in the past
week, and the intensity of their activity. Examples of
moderate, hard, and very hard activities are provided to help
them accurately identify the intensity.
Physical fitness data were collected with the 3-min
stepping test, which was used to detect possible changes in
aerobic fitness by measuring heart rate during the first 15 s
of recovery from stepping. The stepping test has high
reliability (0.92), is sensitive to change [32], and widely
used to assess cardiorespiratory fitness [33].
Blood Sampling and Assays Blood samples were collected
at baseline and 16 weeks between the hours of 8 AM and
1 PM for a majority of the participants (83% at baseline,
68% at 16 weeks). Following centrifugation and separation,
plasma or serum was stored at −80
o C until assays were
conducted. Levels of IL-6, TNF-α, IL-8, and VEGF were
determined in duplicate by commercial ELISAwith internal
controls (R&D Systems, Mpls, MN). Intra-assay coefficient
of variation (CVs) were <8%, and inter-assay CVs were
<7%. Both samples from a given participant were assayed
together [34].
Int.J. Behav. Med. (2011) 18:333–341 335Components of the intervention The overall content of the
intervention included behavioral and cognitive strategies
for implementing dietary modification and increasing
physical activity [35]. The goal was to achieve a modest
weight loss that is sustained, with an emphasis on features
that increase this likelihood, such as acceptance of modest
weight loss and focusing on skills for weight maintenance.
The physical activity component involved encouraging and
promoting regular planned aerobic exercise. The long-term
goal was to achieve an average of at least 1 h/day of
planned exercise at a moderate level of intensity, which is
consistent with the current Institute of Medicine recom-
mendations [36]. The main goal of the dietary guidance
component was to promote a reduction in energy intake
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Topic 
1 
Introduction. Identifying initial 
goals: Meal planning, daily exercise. 
9 
Cognitive aspects: Self talk/affirmations.   
Exercise: Intensity and fatigue. 
17  Dietary supplements. 
2 
Stimulus control and diet. Exercise 
intensity. Estimating calories. 
10 
Scientific update: Nutrition and breast 
cancer, recurrence and progression. 
18  Relapse and interruptions. 
3  Hands on session: Portion control.  11  Stimulus control for exercise.  19  Overview of behavioral techniques. 
4 
Body image/Self acceptance.  
Setting a weight goal.  Life style 
activity (pedometers). 
12 
Body image and overeating episodes. 
Challenges of eating out and strategies. 
20  Weight maintenance skills. 
5  Hands on session: Physical activity.  13  Role of social support.  21  Holidays and interruptions. 
6 
Time management for exercise.  
Energy density of diet. 
14  Exercise: Fun.  22  Revisiting social support. 
7  Benefits/costs of exercise.  15  Exercise: Commitment.  23  Meal satiety. 
8 
Refine meal plan.  Differentiating 
weight loss and primary goals. 
16 
Exercise: Mental health and stress 
management.  Cancer and fatigue. 
24  Weight maintenance skills. 
Fig. 2 Weight loss intervention curriculum topics
Fig. 1 CONSORT Chart for
Healthy Weight Management
Study including recruitment
information
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of 500-1,000 kcal/day by individualized diet modification
that emphasized reduced energy density of the overall diet
[37], while avoiding excessive dietary restraint. The wait
list group participants were provided only general contact
(monthly check-up calls, holiday and seasonal cards, and
mailed communications) without specific reference to
weight management topics through a 12-month period of
data collection. Following that period, they were provided
all written intervention materials and a concise version of
the didactic material, and facilitated discussion was offered
in the format of a 2-day seminar.
Data Analysis
Data were analyzed on all participants (n=68) who had data
for weight, waist, percent body fat, physical fitness,
physical activity, and inflammatory cytokines at baseline
and 16 weeks, following the intensive intervention period,
to explore the association between weight loss (independent
variable) and change in each inflammatory factor (depen-
dent variable). The relationship between physical activity
(independent variable) and change in inflammatory bio-
markers was also examined. Although 12 month data were
collected as part of the parent study, the present findings
describe data from the 16-week data collection period when
blood samples were analyzed for cytokine assays.
Change variables were computed to evaluate group
differences in key study outcomes, such as BMI, weight,
body composition, and level of physical activity. Group
differences in outcome variables at 16 weeks between the
intervention and control groups were assessed with inde-
pendent t tests. After excluding values of cytokine data that
exceeded three standard deviations from the overall mean,
within group differences between baseline and 16 weeks
were evaluated with paired t tests. Spearman correlations
(excluding outliers) examined relationships between cyto-
kines, BMI, percent body fat, and physical activity at
baseline and at 16 weeks. Regression analyses explored the
association between the increase in physical activity levels
(independent variable) and change in each inflammatory
factor (dependent variable), controlling for weight loss and
change in stepping test heart rate. An alpha value ≤0.05 was
considered statistically significant. Data were analyzed
using SPSS for Windows, Version 11.5 (2002) and SAS
statistical software, version 9.2 (2008).
Results
Participant ranged from 33 to 71 years of age. Ninety-four
percent of the participants were non-Hispanic white. The
majority of the participants were married (77%), and many
had completed college or higher levels of education. No
significant differences were found between intervention and
control groups for demographic characteristics such as age,
Intervention Control
(n=44) (n=24)
Variables Mean (SD) Mean (SD)
Age, years 56 (9) 56 (8)
Years of education, years 16 (2) 16 (2)
Body mass index, kg/m
2 30.8 (3.8) 31.3 (5.2)
Weight, kg 83.9 (11.8) 87.2 (14.7)
Waist circumference, cm 101.5 (12.0) 106.7 (13.4)
Total body fat, kg 36.9 (7.5) 40.4 (10.2)
Step test, HR/30 s 60 (8) 57 (7)
Moderate or vigorous physical activity, h/week 3.2 (2.1) 3.7 (3.3)
Table 1 Characteristics of the
study groups at baseline
None of the means are signifi-
cantly different between groups
at baseline
Mean (SD) Intervention (n=44) Control (n=24)
Change in body mass index, kg/m2 −2.1 (1.3)** −0.1 (1.5)
Change in weight, kg −5.7 (3.5)** −0.2 (4.1)
Change in waist circumference, cm −7.1 (6.4)* −2.5 (7.7)
Change in percent body fat
a −4.5 (3.8)** −0.9 (2.3)
Change in step test, HR/30 s −6.0 (8)* −1.0 (6)
Change in physical activity levels, h/week 2.2 (3.3)* 0.3 (3.7)
Table 2 Mean differences in
magnitude of change for key
variables between baseline and
16 weeks
aOne control and two interven-
tion subjects had missing body
composition data (one interven-
tion at baseline; one intervention
and one control at 16 weeks)
*P<0.05; **P<0.0001
Int.J. Behav. Med. (2011) 18:333–341 337levelofeducation,andrace/ethnicity.Similarly,nodifferences
atbaselinewereobservedfor outcome measuressuchasBMI,
weight, and physical fitness or activity levels (Table 1).
According to independent t tests, the magnitude of
reduction in BMI (P<0.0001), weight (−6.8% in interven-
tion and −0.3% in control, P<0.0001), waist circumference
(P<0.05), and percent body fat (P<0.0001) between
baseline and 16 weeks was significantly greater for
participants in the intervention group (Table 2). Addition-
ally, performance on the stepping test indicated better
fitness (P<0.05), and hours of moderate or vigorous
physical activity, between baseline and 16 weeks improved
significantly more for participants in the intervention group
than for controls (P<0.05; Table 2).
According to paired t tests evaluating within-group
differences in inflammatory factors for the intervention
group between baseline and 16 weeks, levels of TNF-α
significantly reduced (P<0.05). A reduction was also noted
for IL-6 level (P=0.06; Table 3). TNF-α was also found to
be decreased at 16 weeks for the control group (P<0.05;
Table 3). No differences were noted for IL-8 and VEGF.
Correlation analysis showed that several inflammatory
factors were associated with key outcome measures for the
participants in the intervention group. Both IL-6 and VEGF
werepositivelycorrelated with BMI at16weeks (r=0.37,P<
0.05 for IL-6, and r=0.44,P<0.01 for VEGF). IL-6 levels at
16 weeks were also positively correlated with performance
on step test (r=0.42, P<0.01). Increased total hours of
moderate or vigorous exercise at 16 weeks was correlated
with favorable reductions in IL-6 (r=−0.35, P<0.05) and
VEGF (r=−0.46, P<0.01) between baseline and 16 weeks.
In a regression analysis using participants in the
intervention group, controlling for change in weight and
change in heart rate/min after the stepping test, increased
level of physical activity was associated with favorable
changes in IL-6 levels (R
2=0.18, P<0.05; Table 4). Other
cytokines did not show significant associations with change
in physical activity.
Discussion
Several possible mechanisms by which weight loss and
physical activity may play a role in reducing breast cancer
risk have been proposed [38]. This small randomized
clinical trial provides an opportunity to evaluate the short-
term effects of weight loss and increased physical activity
on circulating cytokines IL-6, IL-8, TNF-α and VEGF in
overweight or obese breast cancer survivors.
Participants in this study lost nearly 7% of body weight
at the end of the intensive intervention period at 16 weeks.
They also reported increased physical activity and demon-
strated improved cardiorespiratory fitness at this time point.
These findings have promising public health implications
because the vast majority of women who have been
diagnosed with breast cancer are overweight or obese and
exercise at very low levels of intensity and duration [39–
41]. Also, concern with overweight and weight gain is a
Table 3 Within group differences for change in cytokine levels between baseline and 16 weeks
Intervention Control
Mean (SD) N Baseline 16 Weeks N Baseline 16 Weeks
Variables Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) P value
TNFα (pg/mL) 42 5.9 (2.0) 5.4 (1.9) 0.03 24 5.4 (1.3) 4.6 (1.0) 0.0001
IL-6 (pg/mL) 43 1.7 (0.9) 1.4 (0.9) 0.06 24 1.7 (1.3) 1.4 (0.8) 0.33
IL-8 (pg/mL) 43 4.8 (1.7) 5.1 (2.0) 0.29 23 4.5 (1.5) 4.4 (1.9) 0.75
VEGF (pg/mL) 42 29.3 (21.8) 33.5 (27.0) 0.20 23 34.9 (22.5) 31.3 (16.6) 0.38
IL-6 interleukin-6, IL-8 interleukin-8, TNF-α tumor necrosis factor-α, and VEGF vascular endothelial growth factor
Three sigma outliers (one each for IL-6, IL-8, and VEGF and one for both Il-6 and VEGF in the intervention group; one each for IL-8 and VEGF
in the control group) were excluded
Table 4 Regression model of factors associated with IL-6 levels at 16 weeks in the intervention group (n=38)
Variable β-coefficient Significance (P value) R
2
Increase in moderate or vigorous physical activity, hours/week −0.125 0.02
Change in weight, kg 0.01 0.2
Change in heart rate/min after step test −0.01 0.7
0.18
Excluding one 3-sigma outlier
33 Int.J. Behav. Med. (2011) 18:333–341 8common complaint among breast cancer survivors [42]. In
a comprehensive review of observational studies on breast
cancer recurrence or survival, Rock and Demark-Wahnefried
[6] reported that increased BMI and/or excessive adiposity is
a significant risk factor for recurrent disease and/or
decreased survival in a majority of the studies. The findings
from this exploratory study suggest that increased levels of
physical activity and weight loss achieved by participants in
this weight loss intervention may positively influence the
rates of survival in these women by reducing overall
inflammation [19].
The current study also explored changes in levels of
circulating cytokines in these overweight and obese breast
cancer survivors because inflammatory cytokines are
thought to increase with the degree of adiposity [16], and
weight loss has been associated with a reduction in the
levels of inflammatory factors in the general population. An
association with breast pathology and inflammatory cyto-
kines has been noted in previous research studies [9]. In
addition to losing a notable amount of weight, participants
in the intervention group reported an increase in level of
moderate or vigorous physical activity and improved
fitness. During that time period, levels of two inflammatory
factors declined; IL-6 for the intervention group and TNF-α
for both groups. The observation of a decrease in TNF-α
for the control group suggests that the relationship between
obesity and TNF-α production by adipose tissue may not
be clearly established. Recently, Bastard et al. [18]
concluded that the precise role of TNF-α in human obesity
needs further investigation because adipose tissue does not
seem to be directly implicated in the increased circulating
TNF-α levels observed in obese humans. Evidence from
other studies suggest lower levels of TNF-α in breast
cancer patients and a possible anti-tumor effect on breast
cancer cells [12], in addition to its effects on promoting
cellular transformation and metastasis [38]. The precise role
of TNF-α in relation to obesity and physical activity needs
to be investigated further in order to better understand the
decline observed in this study.
We also observed positive associations for BMI, percent
body fat, and IL-6 after the intensive intervention period of
16 weeks. Similar significant positive associations with
CRP, BMI, and waist circumference were identified in a
recent study with breast cancer survivors [43, 44]. Further,
the reduction in IL-6 level was correlated with increased
total hours of moderate or vigorous physical activity in both
univariate and multivariate analysis. These findings are
noteworthy, because even though previous studies have
shown that increased exercise may reduce the levels of
circulating inflammatory factors [21–23], similar findings
have not been previously reported in breast cancer
survivors. In a review of the biological mechanisms that
may explain the affect of physical activity on breast cancer
risk, Neilson et al. [38] concluded that even though weight
loss can decrease levels of IL-6, physical activity may alter
IL-6 levels through an independent mechanism that is not
yet well-understood.
These findings provide some insight into the relationship
between weight loss, increased physical activity, and
inflammatory cytokines, supporting the suggestion that
further research should be pursued in this arena. Even
though higher cytokine levels have been associated with
increased disease risk across studies, identifying the
magnitude of change that could be considered beneficial
for health outcomes remains a challenge, possibly as a
result of multiple factors effecting this relationship [45, 46].
Future research aiming to determine effective levels of
change in cytokines in response to weight loss or increased
physical activity would be valuable. Due to the small
sample size, the findings from the current study should be
considered exploratory. Moreover, because the participants
in this study were mostly non-Hispanic whites, the results
might not be generalizable to breast cancer survivors
representing other racial/ethnic groups.
Understanding the complex associations between obesity,
physical activity, and cytokine levels as they relate to breast
cancer risk has clinical implications because of the potential
roles they may play as part of immunotherapic interventions
[12, 47]. Findings from this study contribute to exploring
the mechanisms by which excessive adiposity increases risk
for recurrence and reduces likelihood of survival following
the diagnosis and treatment of early stage breast cancer. The
findings also contribute to the knowledge base of the
complex interactions between inflammatory factors and
morbidity and mortality relating to cancer.
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